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Abstract
Background: Fesoterodine, a new once daily antimuscarinic, has proven to be an effective, safe, and well-tolerated
treatment in patients with overactive bladder (OAB). To date, no analysis has evaluated the economic costs and
benefits associated with fesoterodine, compared to antimuscarinics in Spain. The purpose of this analysis was to
assess the economic value of OAB treatment with fesoterodine relative to extended release tolterodine and
solifenacin, from the societal perspective.
Methods: The economic model was based on data from two 12-week, randomized, double-blind, and multicenter
trials comparing fesoterodine and tolterodine extended released (ER). Treatment response rates for solifenacin were
extracted from the published literature. Discontinuation and efficacy were based on the results of a 12-week
multinational randomized clinical trial extrapolated to 52 weeks. Changes in health related quality of life were
assessed with the King’s Health Questionnaire, which was transformed into preference-based utility values. Medical
costs included (expressed in € 2010) were antimuscarinics, physician visits, laboratory tests, incontinence pads and
the costs of OAB-related comorbidities, fractures, skin infections, urinary tract infections, depression, and nursing
home admissions associated with incontinence. Time lost from work was also considered. Univariate sensitivity
analyses were also performed.
Results: At week 12, continents accounted for 50.6%, 40.6% and 47.2% of patients in the fesoterodine, tolterodine,
and solifenacin groups, respectively. By week 52, the projected proportions of patients remaining on therapy were
33.1%, 26.5% and 30.8%, respectively. The projected quality- adjusted life years (QALY) gain (compared to baseline)
over the 52-week simulation period were 0.01014, 0.00846 and 0.00957, respectively. The overall treatment cost was
estimated at €1,937, €2,089 and €1,960 for fesoterodine, tolterodine and solifenacin, respectively. Therefore,
treatment with fesoterodine resulted in similar overall costs and greater QALY gain than treatment with either
tolterodine or solifenacin. Sensitivity analysis showed that these results were robust to all changes performed.
Conclusions: The results of this economic analysis suggest that fesoterodine is a cost-effective alternative to
tolterodine and solifenacin for the treatment of patients with OAB in Spain. Fesoterodine provides additional health
benefits while maintain a similar level of costs being a cost-effective treatment strategy from a societal perspective.
Background
Overactive bladder (OAB) is a symptom-driven condi-
tion defined as urinary urgency, with or without urgency
urinary incontinence, usually with increased daytime fre-
quency and nocturnal voiding [1,2]. It is a highly preva-
lent condition, related to an overall OAB prevalence of
11.8% in adults above 18 years of age in Western coun-
tries [3]; affecting men (10.8%) and women (12.8%)
comparably and increased with age [4]. This corre-
sponds to approximately 1 in 8 adults. These numbers
are similar to a 17% prevalence previously reported in 6
European countries (France, Germany, Italy, Spain, Swe-
den, and the United Kingdom) [4] as well as in the Uni-
ted States in adults above 40 years of age [5]. In Spain,
the latest prevalence data showed an OAB and/or urin-
ary incontinence prevalence around 10% in women
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between 50 and 65) [6]. In people over 40, prevalence is
set between 20-22%, and higher than 50% over 65 years
old [6]. Therefore there should be about 3 million peo-
ple over 40 suffering this condition in Spain [7].
OAB has devastating consequences for sufferers both
genders which impact upon their health related quality
of life (HRQoL), self-esteem and relationships [8]. The
constellation of OAB symptoms has a profound negative
effect on patients’ quality of life and general well-being
and can affect social, psychological, occupational,
domestic, physical and sexual aspects of living [9,10].
Despite the high prevalence of OAB and the significant
impact OAB has on patients’ daily lives, up to 75% of
patients remain untreated [4]. The reasons for this lack
of treatment-seeking behaviour include patient embar-
rassment, the misconception that OAB and urinary
incontinence (UI) are natural consequences of ageing,
lack of knowledge regarding available treatments and
unrealistic expectations [11,12]. OAB often precipitates
other medical conditions, such as skin infections, urin-
ary tract infections (UTIs), falls and fractures, and
depression [5,13,14]. All these symptoms and facts
results in a staggering €4,2 billion in the year 2000
OAB-related healthcare cost in 5 European countries
(Germany, Italy, Spain, Sweden, and the United King-
dom); and is predicted to reach € 5,2 billion by 2020, a
25% increase. Incontinence pads were the source of the
largest cost, accounting for approximately 63% of the
annual per-patient OAB management [15].
A probing article recently stated that successful treat-
ment of OAB depends on persistence with the pre-
scribed medication, and efficacy and tolerability are key
influencers of persistence. New antimuscarinic agents
are now available for treating OAB that significantly
improves symptoms of incontinence, urgency and fre-
quency with few adverse effects. An improved efficacy
and tolerability profile should result in greater patient
satisfaction and persistence with treatment during long-
term therapy [16]. Fesoterodine, a new once daily anti-
muscarinic, which has been recently marketed in Spain,
has proven to be an effective, safe, and well-tolerated
treatment in patients with OAB in two large pivotal
phase III studies [17,18]. Fesoterodine has also demon-
strated clinically and statistically significant improve-
ments health-related quality of life (HRQoL) compared
to placebo in subjects with OAB [19].
Health economic analyses assess the implications of
projected outcomes and cost of medical interventions.
Economic assessments of new therapies are often
required by many health decision-making authorities.
These are evaluated in order to properly allocate scarce
healthcare resources. To date, no analysis has been per-
formed to evaluate the economic costs and benefits
associated with fesoterodine related to other existing
antimuscarinics in Spain. Thus, the objective of this ana-
lysis was to assess the 1-year economic value of OAB
treatment with fesoterodine relative to extended release
(ER) tolterodine and solifenacin, from the societal
perspective.
Methods
Economic Model description
A cost-effectiveness analysis (CEA) was performed in
this study through a decision-tree model developed in
an Excel spreadsheet. Cost-effectiveness is typically
expressed as an incremental cost-effectiveness ratio
(ICER): the ratio between the difference in costs and the
difference in benefits of two interventions. A threshold
value is often set by policy makers, who may decide that
only interventions with an ICER below a specific thresh-
old are cost effective, although decision on funding may
be more complex and subject to additional factors. In
Spain, there is no a generally accepted cost-effectiveness
threshold value. However, ICER below €30,000 per
Quality-adjusted-life-year (QALY) gained use to be con-
sidered cost-effective [20]. The decision-tree model was
developed to simulate the typical clinical treatment
pathway of an individual initiating OAB therapy with
fesoterodine 4 mg/day, ER tolterodine 4 mg/day, or soli-
fenacin 5 mg/day (see Figure 1). This economic model
assessed the economic benefits of treating OAB with
incontinence with fesoterodine relative to extended
release tolterodine or solifenacin, based on data from
two 12-week, randomized clinical trials and the pub-
lished literature (see ahead). At weeks 4, 12, 24 and 52
patients were classified as responders (those who are
restored continence or <1 urge urinary incontinence
episode/24 hrs) or non-responders. At four weeks after
treatment initiation, treatment responders are assumed
to continue their initial therapy. Non-responders are
assumed to titrate to the higher dose of fesoterodine or
solifenacin. As an assumption, 50% of responders to fes-
oterodine 4 mg and solifenacin 5 mg were assume to
titrate to the higher dose at week 4, and the same pro-
portion of non-responders in both treatments were elect
not to titrate. Because only one dose of tolterodine is
modelled, all non-responding patients are assumed to
continue with the same treatment. This allows for
patients in the tolterodine arm to have two chances at
treatment response, as there are for fesoterodine and
solifenacin. Responder status is assessed again at week
12. At this point, responders are assumed to continue
treatment and all non-responders are assumed to dis-
continue (i.e., no further titration is allowed and patients
are not assumed to lower previously-titrated doses).
Responders to treatment at week 12 are assumed to
remain responders for the duration of the model unless
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tion is supported by studies of tolterodine that suggest
very little change in treatment efficacy takes place over
the longer term in patients who are compliant with
therapy [21,22]. Therefore, no further changes in drug
efficacy were assumed to occur after week 12 although
some patients were assumed to discontinue for non-effi-
cacy reasons between weeks 12 and 52 [23,24]. Disconti-
nuation, efficacy, and changes in HRQoL results of the
trials were extrapolated from 12 to 52 weeks using the
method of last observation carried forward for all the
comparators.
Following Spanish CEA guidelines, the comparators
considered in the analysis should be the relevant ones in
current clinical practice; i.e. the most commonly used in
the higher number of patients [25]. The 96% of the I.M.S.
reported Spanish antimuscarinic sales [26] are attributed
to fesoterodine, tolterodine and solifenacin; the three most
consumed drugs in Spain; with the rest of antimuscarinics
commercialized in Spain included in the remaining 4% of
the OAB treatment market, and are not considered in this
study due to its low economic impact on health budgets.
As the time horizon for this analysis is 1 year, no discount
rate was included in the analysis [25]. As this analysis was
not carried out on humans, it represents a hypothetical
patient ant the treatment pathway simulation, it was not
needed to get the approval of any ethics committee.
Clinical trial data
Model is populated with data from more than 1.000
patients with OAB and incontinence enrolled in two 12-
week, randomized, placebo controlled, double blind,
international clinical trials [17,18]. These phase III trials
were designed to investigate the efficacy, tolerability,
and safety of fesoterodine 4 mg/day, fesoterodine 8 mg/
day, tolterodine 4 mg/day extended released, and pla-
cebo in patients with OAB and incontinence. Male and
female subjects ≥18 years of age with ≥8 micturitions/24
 Week 4  Week 12  Week 24  Week 52
 Continent
 Continent Feso 4 mg
  Continent Feso 4 mg  Discontinue
 Discontinue
  Continent Feso 4 mg   Incontinent Discontinue
  Discontinue
 Continent Feso 8 mg    * same as above
  Continent Feso 8 mg
 Discontinue
  Feso 4 mg   Incontinent Feso 8 mg   Incontinent Discontinue
  Discontinue
  Discontinue
 Continent Feso 4 mg     *
  Continent Tol 4 mg
 Discontinue
  Continent Tol 4 mg   Incontinent Discontinue
  Discontinue
 Continent Feso 4 mg    * 
  Continent Tol 4 mg
 Discontinue
OAB Patients   Tol 4 mg   Incontinent Tol 4 mg   Incontinent Discontinue
  Discontinue
  Discontinue
 Continent Feso 4 mg     *
  Continent Soli 5 mg
 Discontinue
  Continent Soli 5 mg   Incontinent Discontinue
  Discontinue
 Continent Feso 4 mg    * 
  Continent Soli 10 mg
 Discontinue
  Soli 5 mg   Incontinent Soli 10 mg   Incontinent Discontinue
  Discontinue
  Discontinue
Figure 1 Decision tree model.
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urinary incontinence episode/24 h were included in
these analyses. Trial evaluation endpoints were at weeks
2, 8, and 12 post-treatment starts-up. To estimate the
treatment response rates at week 4, the efficacy and dis-
continuation data at week 8 were chosen as a proxy. As
solifenacin was not a comparator in either clinical trial,
efficacy data (5 mg and 10 mg data combined) were
abstracted from clinical trial published in the literature
[27-30] and enrolling patients with a similar profile than
the ones enrolled in tolterodine and fesoterodine trials.
HRQoL data was extrapolated from the interventions in
the clinical trial. Four studies published the endpoint of
solifenacin restoration of continence. Haab et al. [27]
reported that 52% of patients on either solifenacin 5 mg
or 10 mg were restored to continence at week 12. How-
ever, this group did not report the corresponding value
for the placebo group. Millard and Halaska [28]
reported restoration of continence for those with severe
incontinence at baseline (15.3%, 28.4%, and 30.5% for
placebo, solifenacin 5 mg, and 10 mg, respectively).
Wagg et al. [31] reported 49.1% and 47.3% of elderly
patients on solifenacin 5 mg and 10 mg, respectively,
and 28.9% of patients on placebo had restoration of con-
tinence. Because fesoterodine trial populations include
non-elderly subjects, the analysis of phase III clinical
trials by Cardozo and colleagues was chosen to make
assumptions on such segment of population [29]. This
study examined data from 2,030 incontinent subjects. Of
patients incontinent at baseline, 34% were restored to
continence at week 12, and 51% and 52% were restored
to continence in the solifenacin 5 mg and 10 mg groups,
respectively. These data correspond to a relative risk
(RR) of 1.50 and 1.53, respectively, compared to placebo.
We applied these RRs to the placebo values at weeks 12
to obtain an estimate of the solifenacin efficacy. Efficacy
at week 2 or week 8 is also assumed to be the RR multi-
plied by the corresponding placebo value. Efficacy
values, measured as percentage of patients with resolu-
tion of incontinence, are shown in Table 1.
Some published data have not shown 12-week discon-
tinuation rates for antimuscarinics to be significantly
different than placebo [30]. Therefore, the values consid-
ered in this analysis are equal to placebo discontinuation
(Table 1). Fesoterodine phase III clinical trials were also
t h es o u r c ef o rt h ep e r c e n t a g eo fp a t i e n t sw i t hn o c t u r i a
at baseline (48.58%) and for the percentage of patients
with nocturia at baseline without nocturia at W12 is
shown in Table 1.
Costs
The cost, measured in Euros, of each treatment arm is
the sum of purchased medical and non-medical
resources used and non purchased resources (lost
productivity of the patient or unpaid family member/
caregiver support). Both direct and indirect costs related
to OAB were considered in the basecase analysis follow-
ing a societal perspective that is recommended in Span-
ish CEA guidelines [25]. Additionally, the payer
perspective (Spanish National Healthcare system, which
considered only direct costs) was obtained and pre-
sented separately as a sensitivity analysis [25]. Costs
inputs were taken from the published literature and
expressed in €2010. Direct medical costs included were
antimuscarinic drugs, physician visits, laboratory tests,
incontinence pads, and costs of OAB- or incontinence-
related co morbidities (fractures, skin infections, urinary
tract infections, depression, and nursing home admis-
sions all of them associated with incontinence), and the
cost of treating constipation adverse events (Table 2).
Health care resource utilization included is showed in
Table 3.
The probability of OAB-related co morbidities
depended on the patients’ responder and treatment sta-
tus. Studies have shown the risk of falls and fractures,
skin infections, urinary tract infections, to be positively
associated with OAB and ther i s ko fd e p r e s s i o na n d
nursing home admissions to be associated with OAB
with incontinence. Patients with controlled OAB have
lower risk of co morbidities than non-responders or
untreated patients (Table 3). Skin infections and UTIs
have the possibility of occurring more than once per
year, and the expected number of events per person is
included. The mean numbers of UTI per patient for
these two populations are 0.3 and 0.7, respectively. To
calculate the average number of UTIs per patient
experiencing one, the following formula was used (a
representative calculation for successfully-treated
patients is shown):
# UTIs/UTIpatient =
0.3UTIs
Total pop
×
Total pop
19% UTI patient
= 1.579 UTIs/UTI patient
Analogously, we calculate the expected number of
UTIs per unsuccessfully-treated patient as well as the
expected number of skin infections for both treatment
categories. The utility decrements for fracture, depres-
sion, and nursing home are also considered in the analy-
sis (Table 3), with its corresponding literature sources.
An assessment of the indirect productivity costs asso-
ciated with OAB and incontinence was also included.
Lost productivity at work due to OAB can come from
many sources. For one, frequent voiding during sleep
time (nocturia) can deprive one of needed sleep,
mimicking the symptoms of insomnia. We assume the
decreased productivity during work hours for those with
nocturia relative to those without nocturia to be 9.2%
[32], representing the difference between the percent
work impairment for patients with nocturia (13.8%) and
Arlandis-Guzman et al. BMC Urology 2011, 11:9
http://www.biomedcentral.com/1471-2490/11/9
Page 4 of 11control patients (4.61%), Table 2. Another cause for lost
work is the presence of incontinence, where patients
may choose to work fewer hours because of their condi-
tion. Data show women who work for pay report work-
ing fewer hours per week (38 vs. 30) [33]. Incontinent
men with OAB factor their symptoms into decisions
about location and hours worked more than continent
men or women with OAB and more than twice as
much as women with incontinence (21% vs. 8%). A con-
servative assumption to capture the monetary value of
this productivity loss would be to assume those inconti-
nent patients who are employed work 21% fewer hours
than those without incontinence (the percent difference
between the number of hours worked per week for
women without incontinence versus women with incon-
tinence [38 hours-30 hours]/38 hours). Spanish employ-
ment and wage data were entered into the model to
estimate the decreased productivity while at work due
to interrupted sleep by nocturia episodes and lost time
from work due to incontinence (Table 2). The model
inputs the productivity costs of each treatment arm
compared to no-treatment, as relative productivity gains.
As explained, incontinence and nocturia episodes were
related, respectively, with reduced work hours and lost
productivity while at work and their associated costs. If
no treatment is considered, higher productivity costs are
observed compared to receiving an adequate treatment.
For this reason, negative values (or productivity gains)
would be obtained for each treatment arm compared in
this study.
Effectiveness
In this analysis, effectiveness of medical interventions
was expressed in term of Quality-Adjusted-Life-Years
Table 1 Efficacy (% resolution of incontinence) and discontinuation data included into the economic model
% Resolution of incontinence (<1 episode/24 hrs) W2 W8 W12 W12|W8 W12|~W8
Placebo 20,99% 34,66% 27,84% 80,33% 14,16%
Fesoterodine 4 mg 30,41% 50,00% 43,67% 87,34% 21,05%
Fesoterodine 8 mg 40,59%
a 55,38%
a 50,21% 90,65% 24,20%
Tolterodine 29,23% 49,47% 38,18% 77,17% 13,04%
Solifenacin 5 mg
c 31,49% 51,99% 41,76% 80,33%
d 21,24%
Solifenacin 10 mg
e 32,11%
a 53,01%
a 42,58% 80,33%
d 21,66%
b
Other data % Nocturia (> = 2 episodes/night) % of patients with
nocturia at baseline without nocturia at W12
Constipation
Placebo 54,34% 1,99%
Fesoterodine 4 mg 55,56% 4,15%
Fesoterodine 8 mg 55,90% 6,01%
Tolterodine 57,69% 2,76%
Solifenacin 5 mg 54,34%
i 3,53%
j
Solifenacin 10 mg 88,72%
j 7,72%
j
Discontinuation W2 W8 W12 W24
f W52
f
Placebo 100% 92,84% 90,64% 79,32% 59,27%
Fesoterodine 4 mg 100% 92,67%
g equal to placebo data
h
Fesoterodine 8 mg –– equal to placebo data
h
Tolterodine 100% 95,76% equal to placebo data
h
Solifenacin 5 mg 100% 94,06% equal to placebo data
h
Solifenacin 10 mg –– equal to placebo data
h
The symbol “|” denotes conditional response rates; the response at week 12 given response at week 8. The symbol “~” denotes non-response; no-response at
week 12 given no-response at week 8.
Source: Fesoterodine phase III trials, except when a different source is described [17,18].
a - values not used in the decision tree; only used to calculate conditional response rates.
b - conditional response rates estimated by applying the W8 low dose: high dose response ratio to the W12|~W2(~W8) non-titrating response rate.
c - equal to 1,5 times the placebo rates [29].
d - conditional response equal to placebo rate.
e - equal to 1,5294 times the placebo rates [29].
f - W24 and W52 values were extrapolated from clinical trial data using an exponential decay curve fitted to W2, W8, and W12 discontinuation values.
g - discontinuation rate of fesoterodine 4 mg at W8 in the trial data was greater than that of placebo at W12, therefore this value was set equal to the W12 rate.
h - discontinuation rates at week 12 were found to be not statistically significant for any treatment [30], therefore the values are equal to placebo
discontinuation.
i - relative rates from published literature [42]; solifenacin 5 mg not found to be significantly different than placebo; solifenacin 10 mg 63.28% higher than
placebo.
j - relative rates from published literature [29]; solifenacin 5 mg 1,778 times placebo; solifenacin 10 mg 3,889 times higher than placebo.
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disease specific HRQL tool during the trial: the King’s
Health Questionnaire [34], which was transformed into
preference-based utility values for responders and non-
responders [35]. KHQ is an instrument specifically
designed to assess the impact of bladder problems on
HRQL in women and has been shown to be reliable,
internally consistent and valid in men and women [34].
The items of the KHQ cover 5 domains: role limitations;
physical functioning; social functioning; emotional pro-
blems; sleep disturbance and general health. Each
patient’s 5 domain scores from the KHQ were incorpo-
rated into a regression algorithm developed by Brazier
et al. to generate preference-based utilities [35]. The
authors have previously used this approach to estimate
preference-based utilities from the SF-36 [36]. KHQ
responses were collected from trial participants at base-
line and again at week 12 (Table 3). Utility for patients
not on therapy was assumed equal to the baseline value.
The QALY gains from baseline to week 12, from week
12 to week 24, and from week 24 to week 52 were cal-
culated based on patient’s treatment status (continent,
incontinent, or no treatment). The difference between
week 52 utilities and baseline utilities for responders
and non-responders were the effect measure in the cost-
effectiveness ratio. As described in Table 3, fracture,
depression, and nursing home admissions are assumed
to be associated with a decrement in utility relative to
not having these conditions. The percent decrease is
included as a model condition.
Cost-effectiveness analysis (CEA)
For each of the treatment interventions, the model cal-
culates the expected total one-year costs (including both
direct and indirect costs). The model also determines
the expected proportion of patients on each treatment
having restoration of continence at the end of 1 year
and the QALYs gained for each intervention. These out-
puts are combined to create the incremental cost effec-
tiveness ratio (ICER), representing the additional cost
associated with fesoterodine treatment divided by the
additional QALYs gained with fesoterodine treatment
relative to tolterodine and solifenacin, respectively.
Sensitivity analysis
Several univariate sensitivity analyses of fesoterodine
versus tolterodine ER or solifenacin were performed in
order to find if the results were robust to changes in
main assumptions or inputs of the analysis: trial time
horizon, co morbidities costs and rate per year, utility
estimates, direct medical services costs, utilization and
productivity data, proportion of continent patients at 12
and 52 weeks, and proportion of responders to fesotero-
dine 4 mg and solifenacin 5 mg who elect to titrate to
the higher dose at week 4, as well as the proportion of
non-responders who elect not to titrate. All the variables
were changed in a range of ±25%, a plausible range of
variation of both costs and health effects. Following
Spanish CEA guidelines [25], the payer perspective
results (Spanish National Healthcare system, which con-
sidered only direct costs) were obtained and presented
separately as a sensitivity analysis.
Results
Clinical and cost-effectiveness results are shown in
T a b l e4a n dF i g u r e2 .A tw e e k1 2 ,t h ep r o p o r t i o no f
continent patients on each treatment at the end of the
model period (responders) was higher for fesoterodine
and solifenacin than for tolterodine. By week 52, the
projected proportions of patients remaining on therapy
was again higher in the fesoterodine arm of the study.
The projected quality- adjusted life years (QALY) gain
(compared to baseline) over the 52-week simulation per-
iod showed greater gain for fesoterodine in comparison
with the other two drugs evaluated, while the overall
treatment costs were similar among the three drugs
(Figure 2). However, as the analysis was deterministic,
did not allow for a statistical comparison between drugs.
These results are related to the lower total treatment
costs of fesoterodine in 52 weeks due to the proportion
Table 2 Direct medical and productivity costs included
into the fesoterodine economic model
Resource costs Costs Source
Cost per incontinence pad 0.58 € [43]
Cost of general practitioner visit 26.78 € [44]
Cost of specialist visit 58.60 € [44]
Cost of laboratory tests (urinalysis) 2.56 € [44]
Constipation cost/day
a 0.16 € [44]
Fesoterodine 4 mg (cost/day, with taxes) 1.70 € [43]
Fesoterodine 8 mg (cost/day, with taxes) 2.72 € [43]
Tolterodine ER (cost/day, with taxes) 1.70 € [43]
Solifenacin 5 mg (cost/day, with taxes) 1.67 € [43]
Solifenacin 10 mg (cost/day, with taxes) 2.67 € [43]
Fracture 5,742.8 € [45]
Skin Infection episode 53.1 € [44]
Urinary Tract Infection episode 53.1 € [44]
Depression (€/patient/year) 2,699 € [46]
Nursing Home 14,831.4 [44]
Average hourly wage 13.51 € [47]
Average number of hours worked per week 40 [47]
% Employed in population 59.83% [47]
Decrease in hours worked due to incontinence
b 21.1% [33]
Reduced daytime productivity due to nocturia
c 9.2% [34]
aThe mean cost/day per patient of managing constipation includes a daily
dose of oral laxative.
bWomen without incontinence report working 38 hours/
week vs. 30 hours for women with incontinence.
c 13.8% work impairment for
patients with nocturia vs. 4.61% impairment for controls.
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the 52-week period. Therefore, treatment with fesotero-
dine resulted in lower overall costs and greater QALY
gain than treatment with either tolterodine or
solifenacin.
Sensitivity analysis showed that, for the majority of
plausible scenarios, the results obtained were robust to
all changes performed in the inputs data considered,
consistently showing similar cost but higher effective-
ness for fesoterodine over the other compared antimus-
carinics (cost-saving ICERs), except when the time
horizon was changed to 12 weeks. Nevertheless, if the
total duration of treatment were reduced to approxi-
mately 3 months only, fesoterodine would still continue
Table 3 Healthcare resource utilization and other data included into the fesoterodine economic model
Input Controlled (continent) Uncontrolled (incontinent) Untreated
(incontinent)
Source
Proportion using incontinence pads 0% 67% 67% [24]
Number of incontinence pads/day 0 4.23 4.23 [48]
Number of general practitioner visits/
month
0.133* 0.2 0.2 [48]
Number of specialist visits/month 0.117* 0.15* 0.15 [48]
Number of laboratory tests/month 0.033* 0.078* 0.078 [48]
OAB-related Co morbidities: rate per year
Fracture: 6-month probability of a fall
with fractures (4% decrease in utility
values [49]**)
2.5% 5.3% 5.3% [48,50]
Skin infection: 6-month probability 10.7% (0.3 infections per person in
entire population) (2.8 events/affected
patient)
9.3% (0.6 infections per person in
entire population) (6.5 events/affected
patient)
9.3% [48]
UTI: 6-month probability 19% (0.3 infections per person in entire
population) (1.6 events/affected
patient)
30.7% (0.7 infections per person in
entire population) (2.3 events/affected
patient)
30.7% [48]
Depression (48%
decrease in utility values
[51])***
% female in
clinical trial
data
- 80.87% OAB w/UUI**** - [52]
Women 9.10% 18.90% - [52]
Men 4.30% 18.60% - [52]
Overall 8.08% 18.84% - [52]
Nursing home: Admission
rate per 1000 patient-
years
Women 31 73 73 [53]
Men 24 98 98 [53]
(% decrease in utility
values [49])*****
Overall 29.5 78.3 78.3 [53]
Utility values [17,18] 0.9569 0.9412 0.9332
(baseline
value)
*Bolge et al. 2006, showed that successfully-treated patients saw a GP 25% fewer times than unsuccessfully-treated patients. Additionally, the mean number of
non-GP visits in past 6 months was 0.9 and 0.7, respectively for incontinent and continent patients. Bolge et al 2006 also showed the following number of
urinary test: 0.47 and 0.2 urine tests/patient over last 6 months, respectively for incontinent and continent patients. **Reported wrist fracture utility was 0.96.
Assumed 0.7 utility for 7 weeks, referenced from National Osteoporosis Foundation review. ***Women with urinary incontinence with major depression have
utility of 0.45. Women with urinary incontinence without major depression have utility of 0.86. 0.45 represents a 48% reduction from 0.86. This means a patient
experiencing depression would have 48% reduction in QALY gain than a comparable patient experiencing no co morbidities. ****By using the proportion of
women and men in the trial data (80.87% women, 19.13% men), we calculated the weighted average of the above data for inclusion into the model. *****There
are no published data to provide the difference in utility of OAB patients in and out of nursing homes. One estimate is to use the utility value of nursing home
admission due to hip fracture provided in the UK HTA (0.4), but this value would be an overestimation of the utility decrement for our OAB population since
patients who enter the nursing home due to a hip fracture are in much worse physical condition (and, it follows, utility) than patients entering a nursing home
due to OAB and/or incontinence. For this reasons, no decrease in utility value is considered.
Table 4 Outcomes of the OAB economic model for the base-case scenario
Treatment Continent at Week 12 Continent at Week 52 QALY gain Total costs (€) ICER
Fesoterodine 50.6% 33.08% 0.01014 1,937 -
Tolterodine 40.6% 26.53% 0.00846 2,089 Cost-saving
Solifenacin 47.2% 30.85% 0.00957 1,960 Cost-saving
ICER = Incremental cost-effectiveness ratio.
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Page 7 of 11being a cost-effective option, with an incremental cost-
effectiveness ratio of 574€ and 14,568€ compared to tol-
terodine and solifenacin, respectively when the NHS
p e r s p e c t i v ei sa n a l y z e do n l y( T a b l e5 ) .I ft h es o c i e t a l
perspective is considered, then, fesoterodine would not
be cost-effective relative to solifenacin for treatment
duration of 12 weeks or less only. On the other hand,
changing proportions of continent subjects modified the
ICERs of fesoterodine relative to the other comparators
only when the percentages were reduced by a 25% (table
5). However, ICERs of fesoterodine over tolterodine and
solifenacin were, respectively, of €39,447 and €17,814
per QALY gained, which are still in the range of accep-
table cost-effectiveness in Spain.
Discussion
This decision-tree model cost-effectiveness analysis, the
first one that compares fesoterodine and other salient anti-
muscarinics in Spain, showed that the treatment with feso-
terodine resulted in similar overall costs but greater QALY
gain than treatment with either tolterodine or solifenacin.
In other words, fesoterodine acquisition cost is outweighed
by the lower costs related to both direct and indirect
resources used considered in this study. This analysis tried
to be as much robust as possible, including the relevant
comparators (the ones that represent 96% of the Spanish
year 2010 OAB treatment market), the adequate efficacy
data and the adequate costs. Additionally, several
univariate sensitivity analyses were done, to demonstrate
the strength of the assumptions. As explained in the
results section, fesoterodine continued being the dominant
option in most sensitivity analyses done, particularly when
the time horizon of analysis is set at 52 weeks. When the
time horizon is changed to 12 weeks only (this happening
in some particular patients who abandon the OAB treat-
ment rapidly), fesoterodine would still be a cost-effective
option when the NHS perspective is considered only:
incremental cost-effectiveness ratios per QALY gained of
574€ and 14,568€ compared to tolterodine and solifenacin,
respectively. However, if it is considered the societal per-
spective in the 12-weeks scenario, fesoterodine would be
cost-effective relative to tolterodine only. Nevertheless, the
plausibility of this scenario is really low even considering
than persistence rate with antimuscarinics has been
showed to be lower than with other treatments for chronic
conditions [16]. At least, in the case of solifenacin persis-
tence, it has been communicated to be above 90% after 12
weeks of starting the therapy [27].
The model is considered to be comprehensive by
including several aspects of OAB affecting the overall
economic burden of disease. These include the cost of
incontinence pads and the cost of lost productivity due
to impairment at work or lost time at work due to OAB
symptoms. Also, it includes the cost of associated co
morbidities arising with uncontrolled OAB. The main
reason of incorporating indirect costs is due to their
-1 €
-1 €
0 €
1 €
1 €
2 €
2 €
3 €
3 €
Productivity -678 € -548 € -669 €
Comorbidities & Constipation 1.708 € 1.808 € 1.734 €
Incontinence Pads 336 € 379 € 348 €
Medical 152 € 155 € 153 €
Rx  419 € 295 € 394 €
Fesoterodine Tolterodine Solifenacin
Total 1.937 € Total 2.089 € Total 1.960 € 
Figure 2 Cost outcomes of the OAB economic model by drug (base case scenario).
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Page 8 of 11relevance for OAB. Kobelt et al (2003) [32] conclude
that in an otherwise healthy and professionally active
group of individuals, waking at night to void, signifi-
cantly diminishes their overall well-being, vitality and
productivity, leading to a significant level of indirect and
intangible costs. Additionally, over 21% of the OAB
population worried about interrupting meetings with
frequent trips to the toilet and 3% of the population
changed jobs or were fired because of their bladder
control problems [37]. Considering these figures, lost
productivity and lost wages were included in this analy-
sis. Nevertheless, results are consistent with base case
scenario even if indirect costs are not included in the
analysis and the perspective of National health System is
analyzed solely.
As in all scientific works, this analysis includes limita-
tions and strengths. One of the strengths of the model is
the use of the clinical trial data for the comparison of all
alternatives, which ensures comparable patient popula-
tions among the treatments. However, unlike in the
actual trial, the model assumes patients whose OAB is
not controlled by treatment at each assessment point will
discontinue therapy at that point, replicating a treatment
pattern more reflective of real clinical practice. On the
other hand, solifenacin was not included in the clinical
trial and was modelled using published data. In order to
diminish the possible impact in the results of solifenacin
data, the meta-analysis of phase III clinical trials by Car-
dozo and colleagues was chosen [29], which examined
data from 2,030 incontinent subjects. Inclusion criteria
for these studies were rather similar to the fesoterodine
trials. Another possible limitation is that our analysis was
not able to incorporate the so-called out-of-pocket
expenses, i.e.: incontinence pads not funded by the NHS,
particularly because studies used as a sourcing data for
the analysis were unable to differentiate it. Finally, this
economic model was designed as deterministic, then;
only point estimates are showed not allowing for statisti-
cal comparison between drugs in both costs and effec-
tiveness. However, these results encourages for
development of more sophisticated economic modelling
of such drugs using, i.e., probabilistic approach.
As previously mentioned, this is the first cost-effec-
tiveness analysis performed with Spanish data that com-
pares fesoterodine with another antimuscarinics highly
used in our health context. However, several economic
analyses have been previously published with different
antimuscarinic drugs in other settings. Considering the
comparators included in this analysis, four economic
evaluations have compared solifenacin to ER tolterodine
in three different settings [38-41]. These analyses
showed that treatment with solifenacin was less costly
and more effective than tolterodine. Only one of the
four economic evaluations includes fesoterodine as a
comparator [41], with controversial findings in compari-
son with the results include in our work. The article
included some information based in the experience in
clinical practice use of all antimuscarinics except for fes-
oterodine since it was not marketed yet at the time of
the analysis included in the paper (year 2008). Due to
the lack of available data, fesoterodine inputs were
based on extrapolated assumptions from the use of
other antimuscarinics instead of data from clinical trials.
Table 5 Univariate sensitivity analyses of fesoterodine
versus tolterodine ER or solifenacin
Assumption changed Fesoterodine ICER relative
to:
Tolterodine Solifenacin
Base-case scenario: Results weeks 52,
societal perspective
Cost-savings Cost-savings
Weeks 52, health system perspective Cost-savings Cost-savings
Weeks 12, health system perspective €574 €14,568
Weeks 12, societal perspective €9,106 €216,316
+/- 25% in OAB-related co morbidities
costs
Cost-savings Cost-savings
+/- 25% in OAB-related co morbidities
rate per year in continent patients
Cost-savings Cost-savings
+/- 25% in OAB-related co morbidities
rate per year in incontinent patients
Cost-savings Cost-savings
+/- 25% in utility estimates Cost-savings Cost-savings
+/- 25% in % of responders to
fesoterodine 4 mg and solifenacin 5 mg
that titrate to the higher dose at week 4
Cost-savings Cost-savings
+/- 25% in % of non-responders to
fesoterodine 4 mg and solifenacin 5 mg
that do not to titrate to the higher dose
at week 4
Cost-savings Cost-savings
+25% in % continent patients at week 12 Cost-savings Cost-savings
- 25% in % continent patients at week 12 €39,447 €17,814
+/- 25% in % continent patients at
week 52
Cost-savings Cost-savings
+/- 25% in medical services costs* Cost-savings Cost-savings
Medical services utilization Cost-savings Cost-savings
+/- 25% % of incontinent patients
using pads
Cost-savings Cost-savings
+/- 25% No. pads/day for
incontinent patients
Cost-savings Cost-savings
+/- 25% in # GP visits/month Cost-savings Cost-savings
+/- 25% in # specialist visits/month Cost-savings Cost-savings
+/- 25% in # lab tests/month Cost-savings Cost-savings
Productivity data Cost-savings Cost-savings
+/- 25% in decrease in hours
worked due to incontinence
Cost-savings Cost-savings
+/- 25% in reduced daytime
productivity due to nocturia
Cost-savings Cost-savings
+/- 25% in % employed in
population
Cost-savings Cost-savings
+/- 25% in average hourly wage Cost-savings Cost-savings
ICER = Incremental Cost-effectiveness Ratio. *Costs of incontinence pads,
general practitioners visits, specialist visits, laboratory tests and constipation
cost/day.
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Page 9 of 11Another difference is the type of resources and corre-
sponding cost considered in the analysis, since only
were considered some direct medical costs, while in the
present economic analysis, following Spanish guidelines,
indirect costs were also included [25]. Drug-specific
treatment persistence data were obtained from the
Information Management System database and covered
the 12-month period ending in April 2008. As fesotero-
dine was only on the market since July 2008, treatment
persistence data from longitudinal databases were not
yet available. To approximate the percentage of patients
stopping and switching treatment with fesoterodine in
the base-case analysis, Cardozo et al. [41] used the per-
sistence rates for tolterodine ER, which could potentially
represent a bias against fesoterodine. Finally, the percen-
tage of patients who stop or switch treatment due to
poor compliance was based on expert opinion.
Conclusions
In conclusion, the results of this economic analysis, sup-
ported by sensitivity analyses and despite the limitations
mentioned, suggest that fesoterodine is a cost-effective
alternative to tolterodine and solifenacin for the treat-
ment of patients with OAB in Spain. Fesoterodine pro-
vides additional health benefits while maintain a similar
level of costs being a cost-effective treatment strategy
from a societal perspective and from the National
Health System as well.
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